-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BT-8009 in Transitional Cell Carcinoma (Urothelial Cell Carcinoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BT-8009 in Transitional Cell Carcinoma (Urothelial Cell Carcinoma) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BT-8009 in Transitional Cell Carcinoma (Urothelial Cell...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Omilancor in Ulcerative Colitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Omilancor in Ulcerative Colitis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Omilancor in Ulcerative Colitis Drug Details: Omilancor (BT-11) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Aldoxorubicin in Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Aldoxorubicin in Colorectal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Aldoxorubicin in Colorectal Cancer Drug Details: Aldoxorubicin (INNO-206, DOXO-EMCH, doxorubicin-EMCH) is under...
-
Product Insights
NewEsophageal Diseases – Drugs In Development, 2024
Empower your strategies with our Esophageal Diseases – Drugs In Development, 2024 report and make more profitable business decisions. Esophageal Diseases, which are characterized by weakened muscles and narrowing of the esophageal opening, often lead to difficulties in digestion and swallowing. The esophagus is the tube-shaped muscle that connects the throat to the stomach. Esophageal diseases occur when the esophagus muscle and opening become weak. The most common problem with the esophagus is GERD (gastroesophageal reflux disease). With GERD, a muscle...
-
Product Insights
NewEosinophilic Esophagitis – Drugs In Development, 2024
Empower your strategies with our Eosinophilic Esophagitis – Drugs In Development, 2024 report and make more profitable business decisions. Eosinophilic esophagitis is disease characterized by the presence of a large number of a special type of white blood cell, the eosinophil, that can cause inflammation in the esophagus. Symptoms include poor weight gain, abdominal pain, nausea, and vomiting; coughing; heartburn; and chest pain. Risk factors include weakened immune system, chemotherapy, aspirin and anti-inflammatory medications, chronic vomiting, obesity, and alcohol or cigarette...
-
Product Insights
NewEsophagitis – Drugs In Development, 2024
Empower your strategies with our Esophagitis – Drugs In Development, 2024 report and make more profitable business decisions. Esophagitis is inflammation of the esophagus, often triggered by acid reflux, infections, medications, or allergies. Symptoms include painful swallowing, heartburn, chest pain, and sometimes bleeding. Common types include reflux esophagitis (due to GERD) and infectious esophagitis (caused by viruses, fungi, or bacteria). Diagnosis involves endoscopy and sometimes imaging tests. Treatment focuses on addressing the underlying cause, using acid-suppressing medications, antibiotics, antifungals, or lifestyle...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CX-904 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CX-904 in Solid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.CX-904 in Solid Tumor Drug Details:CX-904 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Drug Details:Abiraterone acetate (DRGT-45) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Omilancor in Ulcerative Colitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Omilancor in Ulcerative Colitis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Omilancor in Ulcerative Colitis Drug Details: Omilancor (BT-11) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Acebilustat in Lymphedema
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Acebilustat in Lymphedema report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Acebilustat in LymphedemaDrug Details:Acebilustat (formerly CTX-4430, EP-501) is under development for the treatment of bullous...